유럽 연합 - 영어 - EMA (European Medicines Agency)

takeda france sas - mifamurtide - osteosarcoma - immunostimulants, - mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. it is used in combination with postoperative multi-agent chemotherapy. safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis.

유럽 연합 - 영어 - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - agalsidase alfa - fabry disease - other alimentary tract and metabolism products, - replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of fabry disease (α-galactosidase-a deficiency).

유럽 연합 - 영어 - EMA (European Medicines Agency)

takeda gmbh - pantoprazole - gastroesophageal reflux - proton pump inhibitors - short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

유럽 연합 - 영어 - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - teduglutide - malabsorption syndromes - other alimentary tract and metabolism products, - revestive is indicated for the treatment of patients aged 1 year and above with short bowel syndrome (sbs). patients should be stable following a period of intestinal adaptation after surgery.revestive is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. patients should be stable following a period of intestinal adaptation after surgery.

유럽 연합 - 영어 - EMA (European Medicines Agency)

takeda gmbh - pantoprazole - gastroesophageal reflux - proton pump inhibitors - short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

유럽 연합 - 영어 - EMA (European Medicines Agency)

takeda gmbh - pantoprazole - gastroesophageal reflux - proton pump inhibitors - short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

유럽 연합 - 영어 - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland - prucalopride succinate - constipation - other drugs for constipation - resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novis healthcare pty ltd - 40535 - lift, patient transfer, sling/harness/strap - this is a single use all round sling designed to work with a patient lift or hoist that will fit the majority of users and hoisting situations in both institutional and homecare environments. the is ideal for hoisting users to and from lying positions and from the floor. they are ergonomically designed for making hoisting comfortable for both the user and the carer, whilst aiming to retain the safety of the user during transfers.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 1000 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; hypromellose; crospovidone; mannitol; purified talc; titanium dioxide; iron oxide yellow; magnesium stearate - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; titanium dioxide; magnesium stearate; iron oxide yellow; purified talc; crospovidone; povidone; hypromellose - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.